Premium
Hemodynamic effects of quinapril, a novel angiotensin‐converting enzyme inhibitor
Author(s) -
Gupta Rakesh K,
Kjeldsen Sverre E,
Krause Lisa,
Kneisley Jill,
Posvar Edward,
Weder Alan B,
Julius Stevo
Publication year - 1990
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1990.116
Subject(s) - quinapril , renal blood flow , vascular resistance , filtration fraction , medicine , angiotensin converting enzyme , hemodynamics , cardiology , cardiac output , ace inhibitor , blood pressure , renal function , essential hypertension , endocrinology
The hemodynamic effects of quinapril, a novel nonsulfhydryl‐containing angiotensin‐converting enzyme (ACE) inhibitor, were assessed in 10 patients with mild‐to‐moderate essential hypertension. Compared with placebo, quinapril (20 mg) administered twice daily for 4 weeks significantly lowered blood pressure by decreasing total peripheral resistance without producing tachycardia, an increase in cardiac output, or a rise in plasma catecholamines. Quinapril significantly reduced renal, but not forearm, vascular resistance. Renal blood flow, glomerular filtration rate, and filtration fraction remained unchanged. Left ventricular wall stress was markedly reduced by quinapril, but during the relatively short treatment period, only a nonsignificant trend toward reduction in left ventricular mass was observed. These findings suggest that quinapril is an effective antihypertensive agent that lowers peripheral resistance without increasing cardiac output or disturbing autoregulation of renal hemodynamics. Clinical Pharmacology and Therapeutics (1990) 48, 41–49; doi: 10.1038/clpt.1990.116